DrugDashboards

Amoxicillin and Clavulanate potassium

Amoxicillin and Clavulanate Potassium · AMOXICILLIN 250 mg/5mL; CLAVULANATE POTASSIUM 62.5 mg/5mL · Suspension · Oral · Cipla USA Inc.

NDC 69097-0098-08 · 150 mL in 1 BOTTLE · ANDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $0.4075 per mL over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4$0.6Mar 2025Sep 2026$0.4075
19 price points · per MLSource: CMS NADAC

Medicaid spend (2025)

$170,931
2,137 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

5Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 5 active manufacturers+5

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for amoxicillin and clavulanate potassium (other) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA065431
TE code
AB
Approval date
Nov 25, 2008
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Amoxicillin and Clavulanate Potassium (Suspension)

LabelerStrengthFirst seenLast seen
Preferred Pharmaceuticals Inc.AMOXICILLIN 600 mg/5mL; CLAVULANATE POTASSIUM 42.9 mg/5mLJul 15, 2026Sep 3, 2026
Cipla USA Inc.AMOXICILLIN 250 mg/5mL; CLAVULANATE POTASSIUM 62.5 mg/5mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.AMOXICILLIN 600 mg/5mL; CLAVULANATE POTASSIUM 42.9 mg/5mLJul 15, 2026Sep 2, 2026
Proficient Rx LPAMOXICILLIN 600 mg/5mL; CLAVULANATE POTASSIUM 42.9 mg/5mLJul 15, 2026Sep 2, 2026
Sandoz IncAMOXICILLIN 600 mg/5mL; CLAVULANATE POTASSIUM 42.9 mg/5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Amoxicillin and Clavulanate potassium — NDC 69097-0098-08," retrieved September 3, 2026, https://drugdashboards.com/drug/69097009808.

Free to cite with attribution — see how the data is put together.